A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
about
Clinical Development of the E75 Vaccine in Breast CancerNovel role of granulocyte-macrophage colony-stimulating factor: antitumor effects through inhibition of epithelial-to-mesenchymal transition in esophageal cancer.Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant settingEradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer.Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.Breast cancer and immunology: biomarker and therapeutic developments.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Breast Cancer Immunotherapy: Facts and Hopes.Immunotherapy for breast cancer: past, present, and future.Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.Progress in nonviral gene therapy for breast cancer and what comes next?Immunotherapy of cancers comes of age.Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.Roles for Innate Immunity in Combination Immunotherapies.Immunotherapy for Breast Cancer: What Are We Missing?Revisiting GM-CSF as an adjuvant for therapeutic vaccines.Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.Virus-like particle display of HER2 induces potent anti-cancer responses.Immunotherapy in Breast Cancer: the New Frontier.SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes.
P2860
Q26745440-C9F49F2B-1F77-4DDA-A848-16EE15A773A8Q33602583-3B332BEB-58D2-4663-88A4-D7838516D4C9Q35816845-4EA357BC-CCE9-4B5C-ACFC-80D4AA7485C0Q37554718-2D094244-B3AE-4231-A300-F920E4650116Q37695311-D27F96EC-A784-4D79-B657-B1A5788DFA67Q37709102-808604CE-D240-4E1C-945A-BDE07367A1CCQ38293525-269F0989-82DA-4EC3-B2F5-B21F95EB5B90Q38584383-1988881C-8134-4650-A3F2-DADAF0639850Q38600417-8CEE67D8-26C9-487F-9DEE-EE0F8F1084BFQ38628198-75B28C1C-293A-47A6-B3A7-E36640F82333Q38787696-AC728633-B8E3-487C-816C-F43954C4EDE1Q38896822-7085ABA5-756C-4EBF-B0F1-D61D571FF16FQ39194052-08346253-89DC-4E24-AD6B-B9233EDE6B13Q40099075-59A4E2EA-3723-485B-8CDC-C0B768512954Q41593373-2F904AC9-47DC-4A6E-A46C-07F31E3E7523Q41996352-C66D77E6-6580-4CF9-897B-D95C3A044DCBQ44668850-CFAB4E4E-58AC-44FD-BC66-A97B9C802CE9Q47604194-0852D3B9-2FF4-4433-941A-B7A315892467Q48328578-2A22B5A2-FD17-4E7B-8F44-6BFC756C7BC0Q52699878-2067804F-23DB-4734-8779-6D110CCEF5F3Q55267620-85CC2524-1AB5-42E5-B9F6-1B6927C9754FQ55342016-56D6271A-0B5D-4C0F-921B-C47BC229EAE8
P2860
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@ast
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@en
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@nl
type
label
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@ast
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@en
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@nl
prefLabel
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@ast
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@en
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@nl
P2093
P2860
P1476
A feasibility study of cycloph ...... ER2+ metastatic breast cancer.
@en
P2093
Antonio C Wolff
Elizabeth Garrett-Mayer
Elizabeth M Duus
James M Leatherman
Jennifer N Uram
John Fetting
Justin M Asquith
Kellie Hirt
Leisha A Emens
P2860
P304
P356
10.1158/2326-6066.CIR-14-0058
P577
2014-08-12T00:00:00Z